23032-21-5 Usage
Description
D-LEUCINE METHYL ESTER HYDROCHLORIDE is a chemical compound derived from the amino acid leucine, characterized by its crystalline powder form and solubility in water. It serves as a versatile building block in the synthesis of peptides and proteins, and is widely utilized across various industries for its diverse applications.
Uses
Used in Pharmaceutical Industry:
D-LEUCINE METHYL ESTER HYDROCHLORIDE is used as a key component in the production of various drugs, contributing to the development of new medications and enhancing the therapeutic potential of existing ones.
Used in Research and Development:
D-LEUCINE METHYL ESTER HYDROCHLORIDE is used as a research tool for the exploration and understanding of peptide and protein synthesis, facilitating the discovery of novel therapeutic agents and advancing scientific knowledge in the field.
Used in Food and Beverage Industry:
D-LEUCINE METHYL ESTER HYDROCHLORIDE is used as a flavor enhancer, improving the taste and aroma of food and beverage products, thereby enhancing consumer appeal and satisfaction.
Used in Nutritional Supplements Production:
D-LEUCINE METHYL ESTER HYDROCHLORIDE is used in the formulation of nutritional supplements, providing essential amino acids to support health and well-being, and contributing to the overall effectiveness of these products.
Check Digit Verification of cas no
The CAS Registry Mumber 23032-21-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,3,0,3 and 2 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 23032-21:
(7*2)+(6*3)+(5*0)+(4*3)+(3*2)+(2*2)+(1*1)=55
55 % 10 = 5
So 23032-21-5 is a valid CAS Registry Number.
InChI:InChI=1/C7H15NO2/c1-5(2)4-6(8)7(9)10-3/h5-6H,4,8H2,1-3H3/t6-/m1/s1
23032-21-5Relevant articles and documents
Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes: 2. Optimization of serine and threonine ether amino acid residues
Sparks, Steven M.,Banker, Pierette,Bickett, David M.,Clancy, Daphne C.,Dickerson, Scott H.,Garrido, Dulce M.,Golden, Pamela L.,Peat, Andrew J.,Sheckler, Lauren R.,Tavares, Francis X.,Thomson, Stephen A.,Weiel, James E.
scheme or table, p. 981 - 985 (2009/08/15)
Optimization of the amino acid residue of a series of anthranilimide-based glycogen phosphorylase inhibitors is described leading to the identification of serine and threonine ether analogs. t-Butylthreonine analog 20 displayed potent in vitro inhibition of GPa, low potential for P450 inhibition, and excellent pharmacokinetic properties.
The first low molecular weight antibiotic from lactic acid bacteria: Reutericyclin, a new tetramic acid
Hoeltzel, Alexandra,Gaenzle, Michael G.,Nicholson, Graeme J.,Hammes, Walter P.,Jung, Guenther
, p. 2766 - 2768 (2007/10/03)
The first chemical proof is available to show that lactic acid bacteria, generally known for their limited metabolite spectrum, are able to produce antibiotics with a broad inhibitory spectrum. The new tetramic acid, reutericyclin (1), opens a new dimension in the discussion regarding the application of lactic acid bacteria in food preservation or for positively influencing the human intestinal microflora.
Opticar Resolution of the D- and L-Amino Acid Family by Liquid-Solid Chromatography
Dobashi, Akira,Oka, Kitaro,Hara, Shoji
, p. 7122 - 7123 (2007/10/02)
-
